Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including ...

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures ...

A new player in radioligand therapies (RLTs), Norway and US-based Actithera, has arrived on the scene with $75.5 million in ...

The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.

This period, known as the Hadean Eon, was characterized by frequent asteroid impacts, including the catastrophic collision that likely formed the Moon. During this chaotic time, Earth was bombarded ...